Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 305.50
Bid: 305.00
Ask: 307.00
Change: -1.00 (-0.33%)
Spread: 2.00 (0.656%)
Open: 300.00
High: 311.50
Low: 300.00
Prev. Close: 306.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Wed, 15th Dec 2021 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

----------

FTSE 100

----------

SOCGEN CUTS BAE SYSTEMS PRICE TARGET TO 620 (660) PENCE - 'BUY'

----------

RBC CUTS ANGLO AMERICAN PRICE TARGET TO 3,150 (3,300) PENCE - 'OUTPERFORM'

----------

JEFFERIES CUTS ANTOFAGASTA PRICE TARGET TO 1,700 (1,800) PENCE - 'BUY'

----------

RBC CUTS BP PRICE TARGET TO 410 (425) PENCE - 'SECTOR PERFORM'

----------

RBC RAISES SHELL B PRICE TARGET TO 2,500 (2,350) PENCE - 'OUTPERFORM'

----------

GOLDMAN SACHS CUTS UNILEVER PRICE TARGET TO 4,700 (4,800) PENCE - 'BUY'

----------

GOLDMAN RAISES TESCO PRICE TARGET TO 335 (320) PENCE - 'BUY'

----------

GOLDMAN RAISES J SAINSBURY PRICE TARGET TO 270 (265) PENCE - 'NEUTRAL'

----------

BARCLAYS CUTS VODAFONE PRICE TARGET TO 165 (170) PENCE - 'OVERWEIGHT'

----------

DEUTSCHE BANK RAISES PEARSON PRICE TARGET TO 625 (570) PENCE - 'HOLD'

----------

BARCLAYS CUTS DCC TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 5,550 (6,900) PENCE

----------

CREDIT SUISSE CUTS RENTOKIL INITIAL TARGET TO 600 (630) PENCE - 'OUTPERFORM'

----------

CITIGROUP CUTS RENTOKIL TO 'NEUTRAL' (BUY) - PRICE TARGET 650 (600) PENCE

----------

FTSE 250

----------

BERENBERG CUTS HARBOUR ENERGY TO 'HOLD' (BUY) - PRICE TARGET 350 (425) PENCE

----------

RBC CUTS HARBOUR ENERGY TO 'SECTOR PERFORM' (OUTPERFORM) - PRICE TARGET 480 (650) PENCE

----------

RBC RAISES OXFORD BIOMEDICA PRICE TARGET TO 1,450 (14,30) PENCE - 'OUTPERFORM'

----------

BARCLAYS CUTS DOMINO'S PIZZA TO 'UNDERWEIGHT' (EQUAL WEIGHT) - PRICE TARGET 495 (500) PENCE

----------

UBS RAISES BALFOUR BEATTY PRICE TARGET TO 390 (370) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES BEAZLEY PRICE TARGET TO 415 (350) PENCE - 'NEUTRAL'

----------

OTHER MAIN MARKET AND AIM

----------

BOFA INITIATES POD POINT WITH 'BUY' - TARGET 450 PENCE

----------

RBC RAISES TULLOW OIL TO 'SECTOR PERFORM' (UNDERPERFORM) - PRICE TARGET 90 (70) PENCE

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

Read more
1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

Read more
1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

Read more
1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

Read more
1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

Read more
1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

Read more
1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

Read more
1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

Read more
1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

Read more
1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

Read more
1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

Read more
3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

Read more
31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

Read more
31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.